To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Part 1 - Healthy Volunteers Clinical Trial

Official title: A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects

Status Terminated

Clinical Trial Summary

This study is designed to enable optimal dose selection of LFF269 for potential future studies by providing additional information about the compounds safety, tolerability, pharmacokinetic and pharmacodynamic profiles.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertension
• Part 1 - Healthy Volunteers
• Part 2 - Patients With Hypertension

• NCT number: NCT02047656
• Study type: Interventional
• Source: Novartis
• Status: Terminated
• Phase: Phase 1
• Start date: August 2013
• Completion date: August 2014